Healthy Clinical Trial
— MENTAkHEALTHOfficial title:
The Effects of the Anti-inflammatory Microbe - Pasteurized Akkermansia Muciniphila (PAM) on Symptoms of Somatic and Mental Stress in Healthcare Professionals
Gut microbiota alterations secondary to chronic stress might serve as a triggering factor towards manifestation of somatic and mental symptoms. The administration of pasteurised A. muciniphila MucT has the capability of supporting microbiota and improving the gut barrier integrity, which might lead to decrease of inflammation and the negative health consequences of stress in healthy participants.
Status | Recruiting |
Enrollment | 200 |
Est. completion date | February 28, 2026 |
Est. primary completion date | August 31, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - Working in a high stress hospital department, like: emergency, trauma, intensive care, surgery, internal diseases; - Written informed consent to participate in this study before any study-mandated procedure; - Body mass index (BMI) =18.5 kg/m2 and = 35 kg/m2; - A willingness and motivation to follow the study protocol. Exclusion Criteria: - Diagnosis of autoimmune, neurological, immunocompromised, thyroid, inflammatory bowel diseases, irritable bowel syndrome, diabetes, cancer, and/or IgE-dependent allergy; - Psychiatric comorbidities, including mental retardation, organic brain dysfunction, or addiction (except nicotine and caffeine), intake of antipsychotic and antidepressive drugs; - Proton pump inhibitors usage; - The use of antibiotics and/or probiotics 4 weeks prior to the study; - Glucocorticosteroids and/or metformin treatment; - Dietary supplementation (except for vitamin D) within the three months before screening; - Specific restrictive (e.g. elimination, vegan, FODMAP, reduction) diet within the three months before screening; - Significant changes in physical activity 4 weeks before the trial entry; - Pregnancy or lactation; - Significant GI surgery within the last 6 months prior to or planned during the study; - Any other medication for management of IBS complaints like peppermint oil, bile acid binders; - Lactose intolerance; - Participation in another study during the last 30 days prior to and during the study; - Any other reason for exclusion as per investigator's judgment, e.g. insufficient compliance with study procedures. |
Country | Name | City | State |
---|---|---|---|
Poland | Center fo Medical Simulation | Szczecin | Zachodniopomorskie |
Poland | Pomeranian Medical University in Szczecin | Szczecin | Zachodniopomorskie |
Lead Sponsor | Collaborator |
---|---|
Pomeranian Medical University Szczecin | Charite University, Berlin, Germany, Imperial College London, MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (MDC) - MDC, SANPROBI SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA SPOLKA KOMANDYTOWA, THE AKKERMANSIA COMPANY |
Poland,
Cani PD, Depommier C, Derrien M, Everard A, de Vos WM. Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms. Nat Rev Gastroenterol Hepatol. 2022 Oct;19(10):625-637. doi: 10.1038/s41575-022-00631-9. Epub 2022 May 31. Erratum In: Nat Rev Gastroenterol Hepatol. 2022 Jun 23;: — View Citation
Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S, Falony G, Raes J, Maiter D, Delzenne NM, de Barsy M, Loumaye A, Hermans MP, Thissen JP, de Vos WM, Cani PD. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. 2019 Jul;25(7):1096-1103. doi: 10.1038/s41591-019-0495-2. Epub 2019 Jul 1. — View Citation
Druart C, Plovier H, Van Hul M, Brient A, Phipps KR, de Vos WM, Cani PD. Toxicological safety evaluation of pasteurized Akkermansia muciniphila. J Appl Toxicol. 2021 Feb;41(2):276-290. doi: 10.1002/jat.4044. Epub 2020 Jul 28. — View Citation
Schneeberger M, Everard A, Gomez-Valades AG, Matamoros S, Ramirez S, Delzenne NM, Gomis R, Claret M, Cani PD. Akkermansia muciniphila inversely correlates with the onset of inflammation, altered adipose tissue metabolism and metabolic disorders during obesity in mice. Sci Rep. 2015 Nov 13;5:16643. doi: 10.1038/srep16643. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Stress intensity | serum dehydroepiandrosterone sulfate (DHEAS) in blood | baseline | |
Primary | Stress intensity | serum dehydroepiandrosterone sulfate (DHEAS) in blood | 1 month | |
Primary | Stress intensity | serum dehydroepiandrosterone sulfate (DHEAS) in blood | 3 months | |
Primary | Cardiovascular marker of stressor intensity | blood pressure | baseline | |
Primary | Cardiovascular marker of stressor intensity | blood pressure | 1 month | |
Primary | Cardiovascular marker of stressor intensity | blood pressure | 3 months | |
Primary | Cardiovascular marker of stressor intensity | heart rate | baseline | |
Primary | Cardiovascular marker of stressor intensity | heart rate | 1 month | |
Primary | Cardiovascular marker of stressor intensity | heart rate | 3 months | |
Primary | Stress intensity | Perceived Stress Scale (PSS-10). Individual scores on the PSS can range from 0 to 40 with higher scores indicating higher perceived stress. | baseline | |
Primary | Stress intensity | Perceived Stress Scale (PSS-10). Individual scores on the PSS can range from 0 to 40 with higher scores indicating higher perceived stress. | 1 month | |
Primary | Stress intensity | Perceived Stress Scale (PSS-10). Individual scores on the PSS can range from 0 to 40 with higher scores indicating higher perceived stress. | 3 months | |
Primary | Psychosocial working conditions | Copenhagen Psychosocial Questionnaire (COPSOQ). The scales of the COPSOQ are formed by adding the points of the individual questions of the scales by giving equal weights to each question. In most cases the questions have five response options. In these cases the weights are: 0, 25, 50, 75, and 100. The scale value is calculated as the simple average | baseline | |
Primary | Psychosocial working conditions | Copenhagen Psychosocial Questionnaire (COPSOQ). The scales of the COPSOQ are formed by adding the points of the individual questions of the scales by giving equal weights to each question. In most cases the questions have five response options. In these cases the weights are: 0, 25, 50, 75, and 100. The scale value is calculated as the simple average | 1 month | |
Primary | Psychosocial working conditions | Copenhagen Psychosocial Questionnaire (COPSOQ). The scales of the COPSOQ are formed by adding the points of the individual questions of the scales by giving equal weights to each question. In most cases the questions have five response options. In these cases the weights are: 0, 25, 50, 75, and 100. The scale value is calculated as the simple average | 3 months | |
Primary | The recognition of the most common mental disorders | Primary Care Evaluation of Mental Disorders (PRIME-MD). The yes/no questionnaire serves as an initial screen for 5 general groups of mental disorders commonly found in the general population | baseline | |
Primary | The recognition of the most common mental disorders | Primary Care Evaluation of Mental Disorders (PRIME-MD). The yes/no questionnaire serves as an initial screen for 5 general groups of mental disorders commonly found in the general population | 1 month | |
Primary | The recognition of the most common mental disorders | Primary Care Evaluation of Mental Disorders (PRIME-MD). The yes/no questionnaire serves as an initial screen for 5 general groups of mental disorders commonly found in the general population | 3 months | |
Primary | Depression | Patient Health Questionnaire-9 (PHQ-9). Nine items, each of which is scored 0 to 3, providing a 0 to 27 severity score.This score can then be referred to the accompanying PHQ-9 Scoring Box to interpret the TOTAL score. | baseline | |
Primary | Depression | Patient Health Questionnaire-9 (PHQ-9). Nine items, each of which is scored 0 to 3, providing a 0 to 27 severity score.This score can then be referred to the accompanying PHQ-9 Scoring Box to interpret the TOTAL score. | 1 month | |
Primary | Depression | Patient Health Questionnaire-9 (PHQ-9). Nine items, each of which is scored 0 to 3, providing a 0 to 27 severity score.This score can then be referred to the accompanying PHQ-9 Scoring Box to interpret the TOTAL score. | 3 months | |
Primary | Depressive state | The Beck Depression Inventory (BDI). When the test is scored, a value of 0 to 3 is assigned for each answer and then the total score is compared to a key to determine the depression's severity. The standard cut-off scores were as follows:
0-18: indicates minimal depression 18-30: indicates mild depression 19-29: indicates moderate depression 30-63: indicates severe depression. |
baseline | |
Primary | Depressive state | The Beck Depression Inventory (BDI). When the test is scored, a value of 0 to 3 is assigned for each answer and then the total score is compared to a key to determine the depression's severity. The standard cut-off scores were as follows:
0-18: indicates minimal depression 18-30: indicates mild depression 19-29: indicates moderate depression 30-63: indicates severe depression. |
1 month | |
Primary | Depressive state | The Beck Depression Inventory (BDI). When the test is scored, a value of 0 to 3 is assigned for each answer and then the total score is compared to a key to determine the depression's severity. The standard cut-off scores were as follows:
0-18: indicates minimal depression 18-30: indicates mild depression 19-29: indicates moderate depression 30-63: indicates severe depression. |
3 months | |
Primary | Anxiety and stress | Depression Anxiety Stress Scale 21 (DASS-21). This is a set of three self-report scales designed to measure the emotional states of depression, anxiety and stress. The rating scale is as follows:
0 - Did not apply to me at all - Applied to me to some degree, or some of the time - Applied to me to a considerable degree, or a good part of time - Applied to me very much, or most of the time. SUBSCALES: DASS_Anxiety = questions 2 + 4 + 7 + 9 + 15 + 19 + 20 DASS_Depression = questions 3 + 5 + 10 + 13 + 16 + 17 + 21 DASS_Stress = questions 1 + 6 + 8 + 11 + 12 + 14 +18 |
baseline | |
Primary | Anxiety and stress | Depression Anxiety Stress Scale 21 (DASS-21). This is a set of three self-report scales designed to measure the emotional states of depression, anxiety and stress. The rating scale is as follows:
0 - Did not apply to me at all - Applied to me to some degree, or some of the time - Applied to me to a considerable degree, or a good part of time - Applied to me very much, or most of the time. SUBSCALES: DASS_Anxiety = questions 2 + 4 + 7 + 9 + 15 + 19 + 20 DASS_Depression = questions 3 + 5 + 10 + 13 + 16 + 17 + 21 DASS_Stress = questions 1 + 6 + 8 + 11 + 12 + 14 +18 |
1 month | |
Primary | Anxiety and stress | Depression Anxiety Stress Scale 21 (DASS-21). This is a set of three self-report scales designed to measure the emotional states of depression, anxiety and stress. The rating scale is as follows:
0 - Did not apply to me at all - Applied to me to some degree, or some of the time - Applied to me to a considerable degree, or a good part of time - Applied to me very much, or most of the time. SUBSCALES: DASS_Anxiety = questions 2 + 4 + 7 + 9 + 15 + 19 + 20 DASS_Depression = questions 3 + 5 + 10 + 13 + 16 + 17 + 21 DASS_Stress = questions 1 + 6 + 8 + 11 + 12 + 14 +18 |
3 months | |
Primary | Occurrence of Irritable Bowel Syndrome | Rome IV criteria | baseline | |
Primary | Occurrence of Irritable Bowel Syndrome | Rome IV criteria | 1 month | |
Primary | Occurrence of Irritable Bowel Syndrome | Rome IV criteria | 3 months | |
Primary | Occurence and severity of gastrointestinal symptoms | Gastrointestinal Symptom Rating Scale (GSRS) | baseline | |
Primary | Occurence and severity of gastrointestinal symptoms | Gastrointestinal Symptom Rating Scale (GSRS) | 1 month | |
Primary | Occurence and severity of gastrointestinal symptoms | Gastrointestinal Symptom Rating Scale (GSRS) | 3 months | |
Secondary | Microbiota composition | next generation sequencing | baseline | |
Secondary | Microbiota composition | next generation sequencing | 1 month | |
Secondary | Microbiota composition | next generation sequencing | 3 months | |
Secondary | A. muciniphila count in stool | real-time quantitative PCR (qPCR) | baseline | |
Secondary | A. muciniphila count in stool | real-time quantitative PCR (qPCR) | 1 month | |
Secondary | A. muciniphila count in stool | real-time quantitative PCR (qPCR) | 3 months | |
Secondary | Total bacteria count in stool | real-time quantitative PCR (qPCR) | baseline | |
Secondary | Total bacteria count in stool | real-time quantitative PCR (qPCR) | 1 month | |
Secondary | Total bacteria count in stool | real-time quantitative PCR (qPCR) | 3 months | |
Secondary | Short chain fatty acids content in stool | quadrupole mass spectrometer and high performance liquid chromatograph | baseline | |
Secondary | Short chain fatty acids content in stool | quadrupole mass spectrometer and high performance liquid chromatograph | 1 month | |
Secondary | Short chain fatty acids content in stool | quadrupole mass spectrometer and high performance liquid chromatograph | 3 months | |
Secondary | Immune phenotypes of peripheral blood mononuclear cells (PBMCs) | single-cell genomics (scRNA-seq and scATAC-seq) analyses (in blood) | baseline | |
Secondary | Immune phenotypes of peripheral blood mononuclear cells (PBMCs) | single-cell genomics (scRNA-seq and scATAC-seq) analyses (in blood) | 1 month | |
Secondary | Immune phenotypes of peripheral blood mononuclear cells (PBMCs) | single-cell genomics (scRNA-seq and scATAC-seq) analyses (in blood) | 3 months | |
Secondary | Inflammatory mediators concentrations in blood | high-throughput protein biomarker analysis with the advent of Proximity Extension Assay | baseline | |
Secondary | Inflammatory mediators concentrations in blood | high-throughput protein biomarker analysis with the advent of Proximity Extension Assay | 1 month | |
Secondary | Inflammatory mediators concentrations in blood | high-throughput protein biomarker analysis with the advent of Proximity Extension Assay | 3 months | |
Secondary | Zonulin concentration in stool | enzyme-linked immunosorbent assay (ELISA) | baseline | |
Secondary | Zonulin concentration in stool | enzyme-linked immunosorbent assay (ELISA) | 1 month | |
Secondary | Zonulin concentration in stool | enzyme-linked immunosorbent assay (ELISA) | 3 months | |
Secondary | Calprotectin concentration in stool | enzyme-linked immunosorbent assay (ELISA) | baseline | |
Secondary | Calprotectin concentration in stool | enzyme-linked immunosorbent assay (ELISA) | 1 month | |
Secondary | Calprotectin concentration in stool | enzyme-linked immunosorbent assay (ELISA) | 3 months | |
Secondary | Lipopolysaccharide concentration in blood | enzyme-linked immunosorbent assay (ELISA) | baseline | |
Secondary | Lipopolysaccharide concentration in blood | enzyme-linked immunosorbent assay (ELISA) | 1 month | |
Secondary | Lipopolysaccharide concentration in blood | enzyme-linked immunosorbent assay (ELISA) | 3 months | |
Secondary | Adiposity | Fat mass/fat free mass evaluated by bioimpedance | baseline | |
Secondary | Adiposity | Fat mass/fat free mass evaluated by bioimpedance | 1 month | |
Secondary | Adiposity | Fat mass/fat free mass evaluated by bioimpedance | 3 months | |
Secondary | Obesity | Body weight | baseline | |
Secondary | Obesity | Body weight | 1 month | |
Secondary | Obesity | Body weight | 3 months | |
Secondary | Dietary habits | the frequency of certain food consumption (rank score) by means of validated Food Frequency Questionnaire (FFQ). | baseline | |
Secondary | Physical activity | International Physical Activity Questionnaire. Results can be reported in categories (low activity levels, moderate activity levels or high activity levels) or as a continuous variable (MET minutes a week). | baseline | |
Secondary | Functions of peripheral blood mononuclear cells (PBMCs) | mass cytometry (CyTOF) | baseline | |
Secondary | Functions of peripheral blood mononuclear cells (PBMCs) | mass cytometry (CyTOF) | 1 month | |
Secondary | Functions of peripheral blood mononuclear cells (PBMCs) | mass cytometry (CyTOF) | 3 months | |
Secondary | Insulin resistance | HOMA-Homeostasis Model Assessment calculated from fasted glycemia and insulinemia | baseline | |
Secondary | Insulin resistance | HOMA-Homeostasis Model Assessment calculated from fasted glycemia and insulinemia | 1 month | |
Secondary | Insulin resistance | HOMA-Homeostasis Model Assessment calculated from fasted glycemia and insulinemia | 3 months | |
Secondary | carbohydrate metabolism | glycated hemoglobin (HbA1c) | baseline | |
Secondary | carbohydrate metabolism | glycated hemoglobin (HbA1c) | 1 month | |
Secondary | carbohydrate metabolism | glycated hemoglobin (HbA1c) | 3 months | |
Secondary | Concentration of blood lipids | Analysis of circulating lipids : total, LDL and HDL cholesterol (mg/dl), triglycerides (md/dl) | baseline | |
Secondary | Concentration of blood lipids | Analysis of circulating lipids : total, LDL and HDL cholesterol (mg/dl), triglycerides (md/dl) | 1 month | |
Secondary | Concentration of blood lipids | Analysis of circulating lipids : total, LDL and HDL cholesterol (mg/dl), triglycerides (md/dl) | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |